4,642 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by Collective Family Office LLC

Collective Family Office LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 4,642 shares of the biopharmaceutical company’s stock, valued at approximately $358,000.

A number of other large investors also recently bought and sold shares of GILD. Arrowstreet Capital Limited Partnership raised its stake in Gilead Sciences by 324.8% in the first quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock worth $1,070,232,000 after buying an additional 13,764,169 shares in the last quarter. Norges Bank purchased a new position in Gilead Sciences in the fourth quarter worth $1,115,186,000. Moneta Group Investment Advisors LLC grew its holdings in Gilead Sciences by 96,759.8% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 10,111,194 shares of the biopharmaceutical company’s stock worth $868,046,000 after purchasing an additional 10,100,755 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Gilead Sciences by 70.6% in the first quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock worth $921,006,000 after purchasing an additional 6,410,047 shares during the last quarter. Finally, FMR LLC grew its holdings in Gilead Sciences by 27.2% in the first quarter. FMR LLC now owns 20,909,082 shares of the biopharmaceutical company’s stock worth $1,734,826,000 after purchasing an additional 4,470,179 shares during the last quarter. Institutional investors own 82.33% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Truist Financial reaffirmed a “buy” rating and issued a $91.00 price target on shares of Gilead Sciences in a report on Wednesday, September 6th. HSBC initiated coverage on shares of Gilead Sciences in a report on Wednesday, September 6th. They issued a “reduce” rating and a $71.00 price target on the stock. BMO Capital Markets dropped their price objective on shares of Gilead Sciences from $100.00 to $95.00 in a report on Tuesday, July 18th. Bank of America raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $88.00 to $95.00 in a report on Friday, September 8th. Finally, Cantor Fitzgerald dropped their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set a “neutral” rating on the stock in a report on Wednesday, July 19th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $90.05.

Insider Activity

In other news, insider Merdad Parsey sold 1,501 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $76.99, for a total value of $115,561.99. Following the completion of the sale, the insider now owns 70,130 shares of the company’s stock, valued at approximately $5,399,308.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, insider Merdad Parsey sold 1,501 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $76.99, for a total transaction of $115,561.99. Following the completion of the transaction, the insider now owns 70,130 shares of the company’s stock, valued at approximately $5,399,308.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 5,000 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $80.00, for a total transaction of $400,000.00. Following the transaction, the chief financial officer now directly owns 107,587 shares of the company’s stock, valued at approximately $8,606,960. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ GILD traded up $0.26 during trading hours on Monday, hitting $75.93. 1,204,523 shares of the company’s stock traded hands, compared to its average volume of 5,780,726. Gilead Sciences, Inc. has a 52-week low of $61.44 and a 52-week high of $89.74. The company has a market capitalization of $94.61 billion, a PE ratio of 17.42, a PEG ratio of 0.83 and a beta of 0.37. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.02 and a quick ratio of 0.91. The firm’s 50-day moving average is $77.28 and its 200-day moving average is $78.79.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.30). Gilead Sciences had a net margin of 20.03% and a return on equity of 37.53%. The business had revenue of $6.60 billion for the quarter, compared to analysts’ expectations of $6.45 billion. During the same period in the prior year, the company posted $1.58 EPS. The firm’s revenue was up 5.4% on a year-over-year basis. Equities analysts forecast that Gilead Sciences, Inc. will post 6.64 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a $0.75 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $3.00 annualized dividend and a dividend yield of 3.95%. Gilead Sciences’s dividend payout ratio (DPR) is 68.97%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.